The effects of gender differences and age on the treatment response to fl uvoxamine were investigated in major depressive Japanese patients. A total of 100 Japanese patients participated in this study. The daily dose of fl uvoxamine was fi xed to 100, 150 or 200 mg in the fourth week. This fi xed dose was maintained until the end of the 6-week study. The patients were divided into 3 groups: younger females, older females, and males. Depressive symptoms were evaluated using the Montgomery and Åsberg Depression Rating Scale (MADRS) at pretreatment and at 1, 2, 4, and 6 weeks after the commencement of the study. Seven of the 100 patients were excluded, and the remaining 93 patients constituted the subjects (50 females, 43 males). The number of intent-to-treat responders and non-responders was 55 and 38, respectively. There was a signifi cant difference in the changes in the time course of the MADRS score and changes in the MADRS scores at each evaluation point between the younger and older females. Younger females demonstrated a signifi cantly better response than older females. The results suggest that fl uvoxamine is more effective in younger female patients than in older female patients.
Introduction
Selective serotonin reuptake inhibitors (SSRIs) are the most widely used drugs for the treatment of depression because their effi cacy is similar to that of tricyclic antidepressants (TCAs); further, they have an advantage over TCAs for tolerability. 1 Despite differences in structure and activity, SSRIs, including fl uvoxamine, share several common features, and there is no evidence for the superior effi cacy of one agent over another. In a review of double-blind comparative studies of fl uvoxamine vs imipramine for treating major depressive patients, no difference was indicated in 12 trials, while fl uvoxamine was found to be the superior antidepressant in 2 trials. 2 Depression occurs more often in women than in men, and differences are also observed between men and women in terms of the clinical features of depression and response to treatments. 3 Kornstein et al 4 suggested that women had an advantage in terms of the response rate to sertraline, while men had a higher response rate to imipramine. In this study, the responder analysis at the end point by menopausal status demonstrated that premenopausal women were signifi cantly more likely to respond to sertraline than imipramine, whereas the response rates to sertraline and imipramine of postmenopausal women were similar. However, Hildebrandt et al 5 demonstrated similar clinical effects with antidepressant (clomipramine vs citalopram, paroxetine, and moclobemide) treatment for male and female patients with major and predominantly melancholic depression. There was also no gender difference in treatment response to sertraline in 6-month treatment of depression. 6 In Japanese depressive patients, there was no signifi cant difference in treatment response to fl uvoxamine and paroxetine between males and females; 7 however, we recently revealed that fl uvoxamine was more effective in younger female patients than in older female and male patients in a preliminary report dealing with 66 patients. A major limitation of this study was the small number of patients, particularly the number of younger females. 8 Therefore, we recruited new patients in order to increase the total number of patients to 100. In the present study, we re-analyzed the effects of gender differences and age on the treatment response to fl uvoxamine in 100 major depressive patients.
Method Subjects
This study included a total of 100 Japanese patients who fulfi lled the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for the diagnosis of a major depressive disorder and whose Montgomery and Åsberg Depression Rating Scale (MADRS) 9 scores at pretreatment were 21 or higher. Patients suffering from other axis I disorders (such as dementia, substance abuse, dysthymia, panic disorder, obsessive-compulsive disorder, and generalized anxiety disorder) and those with axis II disorders as determined by a clinical interview were excluded from the study. Patients with a past history of childhood disorders, and those with severe non-psychiatric medical disorders were also excluded. The subjects were patients aged between 20 and 69 years who had not used any psychotropic drug for at least 14 days before participating in the study. Informed consent was obtained from the subjects after providing them with a complete description of the study. Our study was performed in psychiatric units of general hospitals. Well trained psychiatrists made diagnoses and provided antidepressant treatment for the patients.
Treatment
The same dose of fl uvoxamine was administered twice daily, after dinner and at bedtime, for 6 weeks. The initial daily dose was 50 mg, which was increased to 100 mg after 1 week. After another week, the dose was set to 100, 150, or 200 mg, depending on the clinical judgment of the treating psychiatrists; this fi xed dose was maintained until the end of the study. Patients with insomnia were prescribed 0.25 or 0.5 mg of brotizolam, a benzodiazepine sedative hypnotic, at bedtime. No other psychotropic drugs were permitted during the study.
Data collection
The patients were divided into 3 groups: females aged Ͻ44 years, females aged Ն44 years, and males. For the female patients, we set the cut-off point at 44 years of age because females aged Ͻ44 years have a high potential for the intact gonadotropin-releasing hormone (GnRH) pulse pattern and functioning ovulation cycle. 10 The normal pattern of pulsatile GnRH secretion changes during the early 40s as a consequence of irregularity in hypothalamic pacemaker function; therefore, both phases of the ovarian cycle are affected during the perimenopausal period. 11, 12 Several endocrine changes precede clinical menopause, such as changes in the pattern of pulsatile GnRH secretion; 11 therefore, we used 44 years as the cut-off point to distinguish the fertile period from the peri-/postmenopausal periods. The severity of the depressive symptoms was assessed using MADRS. Assessments were conducted at the baseline and at 1, 2, 4, and 6 weeks after the initiation of fl uvoxamine treatment. A single person rated each patient. A decrease of 50% or higher in the baseline MADRS score was defi ned as a clinical response.
Statistical analysis
We used an intent-to-treat last-observation-carried-forward analysis. The clinical characteristics of the patients, responders, and non-responders were analyzed by a chi-square test or an unpaired t-test where appropriate. The distribution of responders and non-responders in the 3 groups was analyzed by a chi-square test. The changes in the time course of MADRS scores (the mean score at each evaluation point minus the mean score at the baseline) among females aged Ͻ44 years, females aged Ն44 years, and males were analyzed by a repeatedmeasures analysis of variance (ANOVA). The changes in MADRS scores at 1, 2, 4, and 6 weeks among the 3 groups were analyzed by an unpaired t test. Statistical analysis was performed using StatView version 5.0 (SAS Institute INC., Cary, NC). All the tests were two-tailed, and a p value Յ 0.05 was regarded as signifi cant.
Results
Among the 100 patients, 3 stopped visiting our hospitals after the fi rst visit without providing an explanation. We excluded 4 patients from the current analysis because of poor compliance with pharmacotherapy. Therefore, the remaining 93 patients constituted the subjects, who included 50 females and 43 males (mean age ± SD = 48.8 ± 13.7 years). The fi nal daily dose of fl uvoxamine was 50 mg for 7, 100 mg for 15, 150 mg for 8, and 200 mg for 64 patients. Patient characteristics are shown in Table 1 .
The number of intent-to-treat responders and nonresponders was 55 and 38 patients, respectively. No signifi cant difference was observed in average age, number Effect of menopausal status on response to fl uvoxamine of previous depressive episodes, proportion of melancholia and non-melancholia, and severity in MADRS scores at pretreatment between the responders and non-responders (Table 1) . Table 2 shows the distributions and intent-totreat response rates to fl uvoxamine between responders and non-responders. Although the response rate of the females of age group Ͻ44 years was high (75%), there was no signifi cant difference in the distributions of the responders and non-responders between females aged Ͻ44 years and those aged Ն44 years (χ 2 = 2.79, p = 0.09), females aged Ͻ44 years and males (χ 2 = 1.08, p = 0.30), and females aged Ն44 years and males (χ 2 = 0.84, p = 0.36). There was a signifi cant difference in the changes in the time course of the MADRS score between the females aged Ͻ44 years and those aged Ն44 years (F = 2.97, p = 0.02). However, there was no signifi cant difference between females aged Ͻ44 years and males (F = 1.50, p = 0.20), and females aged Ն44 years and males at 6 weeks (F = 0.96, p = 0.43) (Figure 1) . Figure 2 depicts changes in the MADRS scores in the 3 groups. There was a signifi cant difference in the MADRS score at each evaluation point between females aged Ͻ44 years and those aged Ն44 years (1 week: t = -3.45, p = 0.001; 2 weeks: t = -2.71, p = 0.009; 4 weeks: t = -2.11, p = 0.04; and 6 weeks: t = -2.17, p = 0.04). Although a signifi cant difference was observed between females aged Ն44 years and males for the MADRS scores in the fi rst week (t = 2.50, p = 0.015), there was no signifi cant difference at 2 weeks (t = 1.55, p = 0.13), 4 weeks (t = 1.12, p = 0.27), and 6 weeks (t = 1.11, P = 0.27). There was no signifi cant difference between females aged Ͻ44 years and males for the MADRS score at each evaluation point (1 week: t = -0.70, p = 0.49; 2 weeks: t = -0.47, p = 0.64; 4 weeks: t = -0.48, p = 0.63; and 6 weeks: t = -0.68, p = 0.50).
Discussion
The results of this study reveal that the fl uvoxamine treatment signifi cantly improved the changes in the time course of MADRS score and changes in the MADRS scores at each evaluation point in younger female depressive patients (females aged Ͻ44 years) compared with older female patients (females aged Ն44 years). Our results were in agreement with those of a recent study in which the menopause status negatively affected the SSRI treatment response of Caucasian female depressive patients treated in primary care. 13 Kornstein et al 4 hypothesized a mechanism for the effect of gender differences; the female gonadal hormones, particularly estrogen, may play an important role in antidepressant activity, thereby enhancing the response to SSRIs in younger women. Halbreich et al 14 have shown that estrogen enhances monoaminergic activity and augments serotoninergic postsynaptic responsiveness. Several studies have suggested that estrogen augments the response to SSRIs in female postmenopausal major depressive patients. 15, 16 Therefore, we suggested that the augmentation therapy using estrogen was useful for postmenopausal patients who did not response to SSRIs. On the other hand, sex differences in depressive response during monoamine depletions in remitted depressive patients were recently reported. In the study, women experienced greater depressive responses than men during tryptophan depletion inducing hyposerotonengic Effect of menopausal status on response to fl uvoxamine function, but not during catecholamine depletion. 17 Similar results were obtained in another recent study on healthy people. 18 These fi ndings suggest that differential sex effects in serotonengic function may be related to gender differences in the clinical effects of SSRIs.
In conclusion, the present study suggests that fl uvoxamine is more effective in younger female patients than in older female and male patients. The major limitation of this study is the lack of placebo control patients. A second limitation is the relatively small number of younger females. This limitation leads to the possibility of a false negative in the distributions of the responders and non-responders between younger females and older females.
